DIN 02556081 — RYSTIGGO 280 MG
RYSTIGGO is a solution of Rozanolixizumab marketed by UCB CANADA INC. The full Rozanolixizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02556081
- Brand name
- RYSTIGGO
- Active ingredient
- Rozanolixizumab
- Strength
- 280 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- UCB CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Neonatal Fc receptor (FcRn) blocker (monoclonal antibody)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.